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BACKGROUND: Malignant gliomas are the most prevalent type of primary brain tumours but the therapeutic armamentarium for these
tumours is limited. Platelet-derived growth factor (PDGF) signalling has been shown to be a key regulator of glioma development.
Clinical trials evaluating the efficacy of anti-PDGFRA therapies on gliomas are ongoing. In this study, we intended to analyse the
expression of PDGFA and its receptor PDGFRA, as well as the underlying genetic (mutations and amplification) mechanisms driving
their expression in a large series of human gliomas.
METHODS: PDGFA and PDGFRA expression was evaluated by immunohistochemistry in a series of 160 gliomas of distinct World
Health Organization (WHO) malignancy grade. PDGFRA-activating gene mutations (exons 12, 18 and 23) were assessed in a subset
of 86 cases by PCR—single-strand conformational polymorphism (PCR-SSCP), followed by direct sequencing. PDGFRA gene
amplification analysis was performed in 57 cases by quantitative real-time PCR (QPCR) and further validated in a subset of cases by
chromogenic in situ hybridisation (CISH) and microarray-based comparative genomic hybridisation (aCGH).
RESULTS: PDGFA and PDGFRA expression was found in 81.2% (130 out of 160) and 29.6% (48 out of 160) of gliomas, respectively. Its
expression was significantly correlated with histological type of the tumours; however, no significant association between the
expression of the ligand and its receptor was observed. The absence of PDGFA expression was significantly associated with the age
of patients and with poor prognosis. Although PDGFRA gene-activating mutations were not found, PDGFRA gene amplification was
observed in 21.1% (12 out of 57) of gliomas. No association was found between the presence of PDGFRA gene amplification and
expression, excepting for grade II diffuse astrocytomas.
CONCLUSION: The concurrent expression of PDGFA and PDGFRA in different subtypes of gliomas, reinforce the recognised
significance of this signalling pathway in gliomas. PDGFRA gene amplification rather than gene mutation may be the underlying genetic
mechanism driving PDGFRA overexpression in a portion of gliomas. Taken together, our results could provide in the future a
molecular basis for PDGFRA-targeted therapies in gliomas.
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Malignant gliomas are highly heterogeneous and invasive tumours
and account for approximately 70% of all primary brain tumours
(Louis et al, 2007). Histologically, gliomas are classified into several
entities, with astrocytic tumours being the most prevalent type,
followed by oligodendroglial and mixed oligoastrocytic tumours,
and less frequently ependymomas (Louis et al, 2007). According to
the World Health Organisation (WHO), tumours are classified into
four grades of malignancy: grade I generally behave in a benign
fashion, whereas grade II–IV are biologically malignant, diffusely
infiltrating the adjacent brain tissues and ultimately progressing
to glioblastoma (WHO grade IV) (Louis et al, 2007). Although
relatively uncommon, malignant gliomas are associated with
disproportionately high morbidity and mortality, with a median
survival time of 12 to 15 months for glioblastomas and 24 to 60
months for patients with anaplastic gliomas (Lacroix et al, 2001).
Despite advances in understanding glioma molecular pathogenesis
and treatment improvements, little is known about the cause of this
disease and strategies which may result in effective treatment
(Louis, 2006; Wen and Kesari, 2008). Therefore, further investiga-
tion of the molecular basis of gliomagenesis is essential for the
identification of new therapeutic targets for these tumours.
The platelet-derived growth factor receptor A (PDGFRA) is a
transmembrane protein with five immunoglobulin-like repeats in
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the extracellular domain and with a split intracellular tyrosine
kinase domain. PDGFRA belongs to class III family of receptor
tyrosine kinases (RTKs) that also includes PDGFRB, KIT, the
macrophage colony-stimulating-factor receptor and Fl cytokine
receptor (Blume-Jensen and Hunter, 2001). Ligand-activated
receptors trigger downstream signal transduction pathways,
including MAP kinase, PI3-kinase/AKT and JAK/STAT and have
pivotal roles in proliferation, differentiation, invasion and survival
(Blume-Jensen and Hunter, 2001). PDGFRA and its main ligand
PDGFA are key regulators of glial cells proliferation, mainly
oligodendrocytes, and have an important role in normal develop-
ment of the central nervous system (Richardson et al, 1988).
Platelet-derived growth factor (PDGF) has also been implicated
in cancer, including central nervous system tumours (Shih and
Holland, 2006). PDGF and PDGF receptors are commonly
coexpressed in gliomas, suggesting that autocrine PDGF receptor
stimulation may contribute to their growth (Hermanson et al,
1992; Westermark et al, 1995). Glioma-like tumours can be
induced in mice after overproduction of PDGF in mouse brain
(Uhrbom et al, 1998). Taken together, these findings provide
strong circumstantial evidence to suggest that PDGFR signalling
may be a driver of gliomagenesis. Given that PDGFRA is a
transmembrane tyrosine kinase receptor and that these receptors
have been shown to be amenable to exploitation as therapeutic
targets, it seems reasonable to hypothesise that PDGFRA may
constitute a potential target for anticancer therapy in gliomas.
The interest in PDGFR as a cancer drug target has increased with
the availability of clinically useful small-molecule inhibitors, such
as imatinib mesylate (Glivec) and sunitinib (Sutent) (Pietras et al,
2003). Imatinib is an orally available RTK inhibitor, which, in
addition to PDGFRs, also inhibits KIT, c-Abl, Bcr–Abl and Arg
(Capdeville et al, 2002). The clinical efficacy of imatinib is well
demonstrated in chronic myeloid leukaemia and in gastrointest-
inal stromal tumours (GISTs), which are driven by activated forms
of BCR–ABL and mutated KIT or PDGFRA genes, respectively
(Druker et al, 2001; Demetri et al, 2002). In addition, clinical trials
are ongoing using imatinib for the treatment of recurrent
glioblastoma patients (Reardon et al, 2005; Raymond et al,
2008). However, the molecular alterations underlying PDGF
overexpression and response to PDGFR antagonists in gliomas
remain poorly understood. Thus, the aim of this study was to
define the frequency of PDGFRA and PDGFA expression in a large
series of gliomas and to determine whether expression of PDGFRA
is driven by PDGFRA gene mutations and/ or amplification.
MATERIALS AND METHODS
Tissue samples
Representative formalin-fixed paraffin-embedded blocks from one
hundred and sixty consecutive craniotomies for gliomas were
retrieved from pathology archives of the Department of Pathology
of Hospital S Joa˜o, Porto and of Hospital S Marcos, Braga,
Portugal. Cases were classified according to the WHO criteria
(Louis et al, 2007). This series (Table 1) includes 83 astrocytic, 68
oligodendroglial and 9 oligoastrocytic tumours. The mean age of
patients at diagnosis was 45.9±17.6 (range, 2–79 years), with a
female/male ratio of 0.93. Follow-up data were available in 108
patients (range: 0–210 months, mean: 38.4±42.1 months). The
procedures followed in the present study were in accordance with
the institutional ethical committees. All the samples enrolled in
Table 1 PDGFA /PDGFRA expression and PDGFRA amplification in glioma patients and correlation with clinical –pathological data
PDGFA expression (N¼ 160) PDGFRA expression (N¼ 160) PDGFRA Amplification (N¼ 57)a
Parameter N
Negative
(%)
Positive
(%) P-value
Negative
(%)
Positive
(%) P-value N
Not amplified
(%)
Amplified
(%) P-value
Age (years)
X45 83 21 (25.3) 62 (74.7) 0.023* 55 (66.3) 28 (33.7) 0.125 36 28 (77.8) 8 (22.2) 0.515
o45 71 8 (11.3) 63 (88.7) 55 (77.5) 16 (22.5) 20 17 (85.0) 3 (15.0)
Gender
Male 82 13 (15.9) 69 (84.1) 0.355 55 (67.1) 27 (32.9) 0.236 33 28 (84.8) 5 (15.2) 0.196
Female 74 16 (21.6) 58 (78.4) 56 (75.7) 18 (24.3) 20 14 (70.0) 6 (30.0)
Cellular lineage
Astrocytic 83 14 (16.9) 69 (83.1) 0.483 45 (54.2) 38 (45.8) o0.001* 32 24 (75.0) 8 (25.0) 0.334
Oligodendroglial 68 13 (19.1) 55 (80.9) 61 (89.7) 7 (10.3) 23 20 (87.0) 3 (13.0)
Oligoastrocytic 9 3 (33.3) 6 (66.7) 6 (66.7) 3 (33.3) 2 1 (50.0) 1 (50.0)
Histological type (WHO grade)
Pilocytic astrocytoma (I) 9 0 (0) 9 (100) 0.004* 8 (88.9) 1 (11.1) o0.001* 1 1 (100) 0 (0) 0.227
Diffuse astrocytoma (II) 33 1 (3.0) 32 (97.0) 18 (54.5) 15 (45.5) 10 5 (50.0) 5 (50.0)
Anaplastic astrocytoma (III) 5 0 (0) 5 (100) 2 (40.0) 3 (60.0) 2 2 (100) 0 (0)
Glioblastoma (IV) 36 13 (36.1) 23 (63.9) 17 (47.2) 19 (52.5) 19 16 (84.2) 3 (15.8)
Oligodendroglioma (II) 32 9 (28.1) 23 (71.9) 28 (87.5) 4 (12.5) 10 9 (90) 1 (10)
Anaplastic oligodendroglioma (III) 36 4 (11.1) 32 (88.9) 33 (91.7) 3 (8.3) 13 11 (84.6) 2 (15.4)
Oligoastrocytoma (II) 2 1 (50.0) 1 (50.0) 2 (100) 0 (0)
Anaplastic oligoastrocytoma (III) 7 2 (28.6) 5 (71.4) 4 (57.1) 3 (42.9) 2 1 (50) 1 (50)
Malignancy grade (WHO)
Low-grade (I and II) 76 11 (14.5) 65 (85.5) 0.187 56 (73.7) 20 (26.3) 0.333 21 15 (71.4) 6 (28.6) 0.232
High-grade (III and IV) 84 19 (22.6) 65 (77.4) 56 (66.7) 28 (33.3) 36 30 (83.3) 6 (16.7)
Follow-up: mean months±s.d.
Gliomas 108 36.1±8.8 99.9±11.9 0.026* 87.4±12.1 74.9±15.8 0.664 40 43.9±8.5 53.1±19.4 0.580
Glioblastomas (WHO IV) 29 8.6±1.4 16.7±3.5 0.526 12.1±3.2 11.5±1.9 0.576 16 10.2±1.9 12.0±1.0 0.854
aAssessed by QPCR; N¼ number of cases; (*) Statistically significant values (Po0.05).
Molecular alterations of PDGFA and PDGFRA in gliomas
O Martinho et al
974
British Journal of Cancer (2009) 101(6), 973 – 982 & 2009 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
this study were completely anonymised after retrieval of follow up
information.
PDGFA and PDGFRA immunohistochemistry
Representative 3-mm thick sections were cut from formalin-fixed
and paraffin-embedded samples and subjected to immunohisto-
chemical analysis. Immunohistochemistry was carried out using a
LabVision Autostainer (LabVision Corporation, Fremont, CA,
USA) and the streptavidin—biotin–peroxidase complex techni-
que, with rabbit polyclonal antibodies raised against human
PDGFA (clone N-30, dilution 1:80; Santa Cruz Biotechnology,
Santa Cruz, USA), and PDGFRA (dilution 1:175; LabVision
Corporation) as previously described (Carvalho et al, 2005; Reis
et al, 2005). In brief, deparaffinised and rehydrated sections used
to study PDGFA expression were pre-treated by microwaving in
10mM citrate buffer (pH 6.0) three times for 5min at 600W. The
sections used for PDGFRA expression were submitted to heat-
induced antigen retrieval with 10mM citrate buffer (pH 6.0) for
20min in a water bath. After incubation of PDGFA and PDGFRA
primary antibody at room temperature for 30min, the secondary
biotinylated goat anti-polyvalent antibody was applied for 10min
followed by incubation with streptavidin–peroxidase complex.
The immune reaction was visualised by DAB as a chromogen
(Ultravision Detection System Anti-polyvalent, HRP/DAB; LabVi-
sion Corporation). Appropriated positive and negative controls
were included in each run: for PDGFA and PDGFRA, cutaneous-
mucosa transition of the anal region, namely medium calibre
vessels with a muscular layer were used as positive controls. For
negative controls, primary antibodies were omitted. All sections
were counterstained with Gill-2 haematoxylin. As previously
described (Reis et al, 2005), both the distribution and intense
immunoreactivity were semi-quantitatively scored by JML and
ALF independently with the observers blinded to the clinical
information and results of the other molecular tests as follows: ()
(negative), (þ ) (p5%), (þ þ ) (5–50%), and (þ þ þ ) (450%).
Samples with scores () and (þ ) were considered negative, and
those with scores (þ þ ) and (þ þ þ ) were considered positive.
DNA isolation
Serial 10mm unstained section of paraffin blocks were cut, and one
adjacent haematoxylin and eosin-stained (H&E) section was taken
for identification and selection of the tumour tissue. Selected areas
containing at least 85% of tumour were marked and macro-
scopically dissected using a sterile needle (Neolus, 25G–0.5mm).
Tissue was placed into a microfuge tube and DNA isolation was
performed using QIAamp DNA Micro Kit (Qiagen, Hilden,
Germany) as previously described (Basto et al, 2005).
PDGFRA mutations
Pre-screening for mutations in exons 12, 18 and 23 of the PDGFRA
gene was carried out by PCR-single-strand conformational
polymorphism (PCR–SSCP) followed by direct DNA sequencing
of samples that showed a mobility shift in the PCR–SSCP analysis,
as previously described (Reis et al, 2005). Briefly, PCR was carried
out in a total volume of 25 ml, consisting of 1–2 ml of DNA solution,
0.5mM of both sense and anti-sense primers, 200 mM of dNTPs
(Fermentas Inc., Glen Burnie, MD, USA), 1.5–2mM of MgCl2
(Bioron GmbH, Ludwigshafen, Germany), 1 Taq Buffer In-
complete (Bioron GmbH) and 1U of Taq Superhot DNA
Polymerase (Bioron GmbH). The reaction consisted of an initial
denaturation at 96 1C for 10min, followed by 40 cycles with
denaturation at 96 1C for 45 s, annealing at 56–60 1C for 45 s and
extension at 72 1C for 45 s, followed by a final extension for 10min
at 72 1C, in a Thermocycler (BioRad, Hercules, CA, USA). Primer
sequences for exons 12 and 18 were previously reported (Reis et al,
2005), and for exon 23 were 50-GCTCTTCTCTCCCTCCTCCA-30
(sense) and 50-TTTCTGAACGGGATCCAGAG-30 (antisense). PCR
products were mixed with an equivalent volume of the denaturing
loading buffer (98% formamide, 0.05% xylene cyanol and
bromophenol blue). After denaturation at 98 1C for 10min and
quenching on ice, 20 ml of the mixture were loaded onto a gel
containing 0.8 MDE (Cambrex Corporation, East Rutherford,
NJ, USA) for exons 12 and 18 and 1 MDE for exon 23, and 0–3%
Glycerol (0% for exon 12 and 3% for exons 18 and 23). The gels
were run for 20 h at 4 1C for exons 12 and 18 and 20 1C for exon 23.
After the run, the gel was stained with Sybr Gold (Invitrogen Ltd.,
Paisley, UK) and visualised under ultraviolet light in a UV
transilluminator.
Samples showing a mobility shift in the PCR–SSCP analysis
different from the normal pattern were directly sequenced
(Stab Vida, Investigation and Services in Biological Sciences Lda,
Oeiras, Portugal) as previously described (Gomes et al, 2007). All
positive cases were confirmed twice with a new and independent
PCR amplification, followed by direct sequencing.
Analysis of PDGFRA gene copy number status
Quantitative real-time PCR Quantitative real-time PCR (QPCR)
was performed with LightCycler (Roche Molecular Biochemicals,
Mannheim, Germany), using fluorescent hybridisation probes and
fluorescence resonance energy transfer for the detection of PCR
amplification product, following the manufacturer’s instructions.
Briefly, primers and probes were designed to amplify a 124 bp
(exon 18 from PDGFRA gene), and a 147 bp (18S gene) specific
PCR product, where 18S was used as reference gene. PCR ampli-
fication was performed in a 10 ml reaction volume, under the
following conditions: 1 reaction master mix (Lightcycler
FastStart DNA Master Hybridisation Probes kit, Roche Molecular
Biochemicals); 0.2 mM Probes (Roche Molecular Biochemicals);
0.5mM primers; 4mM MgCl2 (Roche Molecular Biochemicals) and
1 ml (20 ngml1) of DNA. The reaction was initiated by a
denaturation step for 10min at 95 1C, followed by 45 cycles with
the following profile of amplification: incubation for 10 s at 94 1C,
specific annealing temperature (57 1C for both genes) for 10 s and
extension at 72 1C for an amplicon dependent time (7 s for 18S and
5 s for PDGFRA), immediately followed by a cooling step for 2min
at 40 1C. Primers and probes for 18S gene were previously
described (Gomes et al, 2007), for PDGFRA were as follow:
50-TCAGCTACAGATGGCTTGATCC-30 (forward primer),
50-GCCAAAGTCACAGATCTTCACAAT-30 (reverse primer), 50-
TGTGTCCACCGTGATCTGGCTGC-FL (donator probe), LC640-
CGCAACGTCCTCCTGGCACAAGG-30 (acceptor probe). The PCR
was performed in duplicate for each studied sample. A series of 10
normal DNA from healthy individuals was investigated to
determine the confidence interval and the s.d. of the calculated
ratios for reference and target gene. Evaluation of data was carried
out using the DDCt method: DDCt¼DCt Tumour DNA – DCt
Normal blood DNA. DCt (threshold cycles) is the Ct of the
reference gene minus the Ct of the target gene. Fold increase of the
target gene PDGFRA was calculated by 2(DDCt) and values 42 and
o5 were defined as aneuploidy and valuesX5 were considered as
gene amplification.
Chromogenic in situ hybridisation The presence of PDGFRA gene
amplification was also assessed by means of chromogenic in situ
hybridisation (CISH) with an in-house generated probe made up
with three contiguous, FISH-mapped and end-sequence verified
bacterial artificial chromosomes (BACs) (RP11-626H04, RP11-
231C18 and RP11-545H22), which map to the PDGFRA locus on
4q12 according to Ensembl V39—June 2006 build of the genome
(http://www.ensembl.org/Homo_sapiens/index.html). The in-
house probe was generated, biotin-labelled and used in hybridisa-
tions as previously described (Lambros et al, 2006; Gomes et al,
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2007). Briefly, heat pre-treatment of deparaffinised sections were
incubated for 15min at 98 1C in CISH pre-treatment buffer (SPOT-
light tissue pre-treatment kit, Zymed Laboratories, San Francisco,
CA, USA) and digested with pepsin for 6min at room temperature
according to the manufacturer’s instructions. CISH experiments
were analysed by three of the authors on a multi-headed
microscope. Only unequivocal signals were counted. Signals were
evaluated at  400 and  630 and 60 morphologically unequivocal
neoplastic cells were counted for the presence of the gene probe
signals. Amplification was defined as 45 signals per nucleus in
more than 50% of tumour cells, or when large gene copy clusters
were seen (Lambros et al, 2006; Gomes et al, 2007). CISH
hybridisations were evaluated with observers blinded to the
clinical information and results of immunohistochemical and
QPCR analysis.
Microarray-based comparative genomic hybridisation The aCGH
platform used for this study was constructed at the Breakthrough
Breast Cancer Research Centre and comprises416 000 BAC clones
tiled across the genome (Arriola et al, 2007). This type of BAC
array platform has been shown to be as robust as high-density
oligonucleotide arrays (Coe et al, 2007; Gunnarsson et al, 2008)
and its actual resolution is approximately 100 kb for 498% of the
genome (Arriola et al, 2007, 2008; Marchio` et al, 2008a). Labelling,
hybridisation, washes, image acquisition and data normalisation
were carried out as previously described (Arriola et al, 2007, 2008;
Huang et al, 2007; Marchio` et al, 2008a, 2008b). Polymorphic BACs
identified in an analysis of 50 male/female and female/female
hybridisations were filtered out. This left a final dataset of 13711
clones with unambiguous mapping information according to the
March 2006 build (hg18) of the human genome (http://www.
ensembl.org). Data were smoothed using the adaptive weight
smoothing (aws) algorithm (Mackay et al, 2009). A categorical
analysis was applied to the BACs after classifying them as
representing gain, loss, or no-change according to their smoothed
Log2 ratio values Threshold values were chosen to correspond to
three s.d. of the normal ratios obtained from the filtered clones
mapping to chromosomes 1–22, assessed in multiple hybridisa-
tions between DNA extracted from a pool of male and female
blood donors as previously described (Arriola et al, 2008; Reis-
Filho et al, 2008) (Log2 ratio of±0.08). Low level gain was defined
as a smoothed Log2 ratio of between 0.12 and 0.40, corresponding
to approximately 3–5 copies of the locus, whereas gene
amplification was defined as having a Log2 ratio 40.40,
corresponding to more than 5 copies (Arriola et al, 2008). These
figures were obtained by comparison with interphase FISH data for
markers at different chromosomal locations (Reis-Filho et al,
2008). Data processing and analysis were carried out in R 2.0.1
(http://www.r-project.org/) and BioConductor 1.5 (http://www.
bioconductor.org/), making extensive use of modified versions of
the packages aCGH, marray and aws in particular.
Statistical analysis
Correlations between categorical variables were performed using
the w2-test. Cumulative survival probabilities were calculated using
the Kaplan–Meier method. Differences between survival rates were
tested with the log-rank test. Two-tailed P-values o0.05 were
considered significant. All statistical analysis was performed using
SPSS software for Windows, version 14.0.
RESULTS
PDGFA and PDGFRA expression
PDGFA and PDGFRA expression was found in 81.2% (130 out of
160) and 29.6% (48 out of 160) of gliomas, respectively.
Immunohistochemical analysis showed that tumour cells express
PDGFA in the cytoplasm (Figure 1A), whereas PDGFRA was
preferentially observed in the cytoplasmic compartment and rarely
on membranes (Figure 1B). PDGFA expression was also observed
in tumour-associated endothelial cells and in basal membrane of
Figure 1 Immunohistochemistry analysis of PDGFA and PDGFRA in gliomas; (A) Glioblastoma with (þ þ þ ) score for PDGFA expression ( 200);
(B) Glioblastoma with (þ þ þ ) score for PDGFRA expression ( 200). (C) Glioblastoma with () score for PDGFA expression in tumour cells and
positive in endothelial cells ( 200). (D) Glioblastoma with (þ ) score for PDGFRA expression ( 200).
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blood vessels in approximately 12% (19 out of 160) of the cases
(Figure 1C). Representative PDGFRA-negative staining is shown in
Figure 1D. Twenty five percent (40 out of 160) of gliomas
coexpressed PDGFA and their receptor PDGFRA; however, no
statistically significant association between the expression of the
ligand and its receptor was observed (P40.05). When the presence
or absence of PDGFA/PDGFRA overexpression (þ þ þ ) was
defined according to histological type, a trend for PDGFA and
PDGFRA coexpression in glioblastomas was found (P¼ 0.069).
PDGFA and PDGFRA expression was significantly correlated
with histological type (P¼ 0.004 and 0.0001, respectively) (Table 1).
When tumours were classified into the three major groups
according to their histogenesis (astrocytic, oligodendroglial and
mixed), only PDGFRA expression was statistically significantly
correlated with astrocytic lineage (Po0.001) (Table 1).
In 22 cases, it was possible to analyse PDGFA and PDGFRA
expression in both primary and recurrent tumours (Table 2).
Overall, the results were concordant; however, we observed loss or
gain of PDGFA and PDGFRA in recurrent tumours of some
patients (Table 2).
No statistically significant correlations were found between
PDGFRA expression and clinical–pathological parameters includ-
ing age, gender, WHO histological grade and prognosis (Table 1).
However, the absence of PDGFA expression was significantly
associated (P¼ 0.023) with age (445 years) and with a poor
prognosis in glioma patients (P¼ 0.026) (Table 1 and Figure 2).
PDGFRA gene mutations
PCR–SSCP analysis for PDGFRA gene mutations in exons 12, 18
and 23 produced optimal results in 86 cases, 30 of which were
PDGFRA-positive tumours. No activating mutations were found.
However, four silent mutations and an intronic insertion were
identified in 45.3% (39 out of 86) of glioma patients (Table 3). Five
patients showed the simultaneous presence of two different
mutations. No association was found between the presence of
PDGFRA gene mutations and PDGFRA expression (P40.05).
PDGFRA gene amplification
Analysis of PDGFRA gene copy number status as defined by QPCR
was successfully performed in 57 gliomas. PDGFRA copy number
changes (ratio 42) were observed in 52.6% (30 out of 57) of
glioma patients: 18 displayed ratios o5 and were considered
representative of aneuploidy/aneusomy and 12 (21.1%) harboured
Table 2 PDGFA /PDGFRA expression and PDGFRA amplification in glioma patients with recurrences
PDGFA expression PDGFRA expression PDGFRA amplificationa
Case Classification (P/R) P R P R P R
58, 59 FA/FA +  +  Amplified Amplified
48, 93 GBM/GBM + + + + Normal Normal
24, 25 GBM/GBM + + + + Normal Normal
168, 169 O/AO  + + + Normal Normal
200, 201 AO/AO + +  + Aneuploid Aneuploid
132, 131 P/P + +   Normal Normal
28, 52, 53 FA/AA/GBM + / + / ND ND
32, 35 GBM/GBM     ND ND
30, 39 GBM/GBM  +   ND ND
88, 89 O/O + +   Normal Normal
103, 104 O/O + +   Normal Normal
188, 209, 190 O/AO/AO + +/+  / ND ND
185, 186 O/AO + +   Normal Normal
98, 100 O/AO + +   Normal Normal
77, 78, 79 O/AO + +   Normal Normal
181, 182 O/AO + +   ND ND
177, 178, 179 O/AO/AO + +/+  / ND ND
92, 101 AO/AO + +  + ND ND
172, 173 AO/AO + + +  ND ND
165,166 AO/O     ND ND
110, 111 AO/AO + +   Normal Amplified
160, 161, 162 AO/AO/AO + +/+  / ND ND
aAssessed by QPCR; P¼ Primary tumour; R¼Recurrent tumour; P¼ Pilocytic astrocytoma (grade I); FA¼ fibrilar astrocytoma (grade II); AA¼ anaplastic astrocytoma (grade III);
GBM¼ glioblastoma (grade IV); O¼ oligodendroglioma (grade II); AO¼ anaplastic oligodendroglioma (grade III); ()¼Negative expression (score 0 and +); (+)¼ Positive
expression (score ++ and +++); ND¼ not done.
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Figure 2 Kaplan–Meier curve illustrating the impact of PDGFA
expression on overall survival (months) of glioma patients.
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ratiosX5 and were considered amplified (Table 1). No statistically
significant associations were found between the PDGFRA ampli-
fication and PDGFRA expression. However, a borderline associa-
tion (P¼ 0.058) was observed between amplification and
overexpression (þ þ þ ). In addition, a statistically significant
association (P¼ 0.038) was found between PDGFRA amplification
and overexpression in grade II diffuse astrocytomas (Table 4).
After statistical analysis, no significant correlations were found
between the PDGFRA gene amplification and clinical–pathological
features (P40.05) (Table 1).
In 12 cases, data on PDGFRA amplification status in both the
primary and recurrent tumours were available (Table 2). In all but
one case (tumours 110 and 111) primary and recurrent tumours
displayed identical PDGFRA copy number status. Interestingly
acquisition of PDGFRA amplification was observed in the
recurrent tumour 111; however, this was not associated with
expression of PDGFRA.
To validate QPCR results we performed CISH in six cases, three
with and three without PDGFRA amplification as defined by
QPCR. CISH analysis of cases defined as harbouring PDGFRA gene
amplification by QPCR revealed clusters of PDGFRA signals in the
nuclei of neoplastic cells (Figure 3A), confirming gene amplifica-
tion. In normal cases, only one-to-two PDGFRA gene signals per
nucleus were found in neoplastic cells (Figure 3B). To further
validate the results of the QPCR analysis, we performed micro-
array-based comparative genomic hybridisation in two cases, one
with and one without PDGFRA amplification as defined by QPCR.
The case without PDGFRA gene amplification by QPCR showed no
changes on chromosome 4 (Figure 4A). In the case with
amplification, the peak of the amplicon on 4q was restricted to
4q12, encompassing a genomic region of 3.7Mb (Figure 4B),
flanked by the BACs RP11-654K2 (54025,329 kb) and RP11-284L3
(57933,681 kb), including the genes: LNX1, CHIC2, GSH2,
PDGFRA, KIT, KDR, SRD5A2 L, TMEM165, CLOCK, PDCL2,
NMU, EXOC1, CEP135, AASDH, PPAT, PAICS, SRP72, ARL9,
HOP, SPINK2, REST, C4orf14, POLR2B, and IGFBP7. Taken
together, the above CISH and aCGH findings provide a robust
validation for the results obtained with QPCR.
DISCUSSION
The PDGF pathway is one of the most consistently altered cellular
signalling system in glial tumourigenesis (Shih and Holland, 2006;
Fomchenko and Holland, 2007). PDGF and PDGFRs have both
been found to be overexpressed in glial tumour cell lines and
tumour surgical samples (Nister et al, 1988, 1991; Hermanson et al,
1992; Black et al, 1996; Di Rocco et al, 1998; Varela et al, 2004).
PDGFRA and PDGFA have been shown to be expressed in tumour
cells, whereas PDGFB and PDGFRB have been found in glioma-
associated endothelial cells (Hermansson et al, 1988; Hermanson
et al, 1992; Plate et al, 1992). Furthermore, studies on the PDGFC
and D ligands, also demonstrate their expression in gliomas;
however, the clinical and biological significance of their expression
remain to be determined (Lokker et al, 2002). Importantly, the
function of PDGF signalling in gliomagenesis has been enlightened
by its potential role in cancer stem cell hypothesis of gliomagen-
esis. It has been suggested that activation of PDGFRA signalling,
directly or indirectly through creating a favourable microenviron-
ment niche, can contribute to the transformation of neural stem/
progenitor cells into glioma tumours (Jackson et al, 2006;
Fomchenko and Holland, 2007; Siebzehnrubl et al, 2008).
Clinical trials evaluating the efficacy of anti-PDGFRA drugs in
patients with glioblastomas are ongoing (Reardon et al, 2005;
Table 3 Sequence variants of PDGFRA gene in glioma patients
Exon Nucleotide change Amino-acid substitution No of cases dbSNP
Exon 12
1686 T4C I562I 1 Not yet described
1701 G4A P567P 6 rs1873778
1777 C4T L593 L 1 Not yet described
Exon 18
2472 C4T V824V 21 rs2228230
2449_50insA IVS18-50insA 15 rs3830355
dbSNP¼ single nucleotide polymorphism database (http://www.ncbi.nlm.nih.gov/SNP/).
Table 4 Correlation between PDGFRA overexpression and PDGFRA amplification in gliomas
PDGFRA amplificationa
Histological type (WHO grade) N PDGFRA overexpression Not amplified (%) Amplified (%) P-value
Pilocytic astrocytoma (I) 1 Negative 1 (100) 0 (0) NP
overexpression 0 (0) 0 (0)
Diffuse astrocytoma (II) 10 Negative 5 (100) 2 (40.0) 0.038*
overexpression 0 (0) 3 (60.0)
Anaplastic astrocytoma (III) 2 Negative 2 (100) 0 (0) NP
overexpression 0 (0) 0 (0)
Glioblastoma (IV) 19 Negative 4 (25.0) 1 (33.3) 0.624
overexpression 12 (75.0) 2 (66.7)
Oligodendroglioma (II) 10 Negative 8 (88.9) 1 (100) 0.900
overexpression 1 (11.1) 0 (0)
Anaplastic oligodendroglioma (III) 13 Negative 11 (100) 1 (50) 0.154
overexpression 0 (0) 1 (50)
Anaplastic oligoastrocytoma (III) 2 Negative 1 (100) 0 (0) 0.500
overexpression 0 (0) 1 (100)
aAssessed by QPCR; Negative expression¼ scores 0, + and ++; Overexpression¼ score +++; (*) Statistically significant values (Po0.05); NP¼ not possible.
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Wen et al, 2006; Desjardins et al, 2007; Newton, 2007; Raymond
et al, 2008). Despite the positive response, none of the new targeted
therapies has shown significant clinical activity as a single agent in
phase II studies (Brandsma and van den Bent, 2007; Raymond
et al, 2008). Currently, combination of anti-PDGFRA drugs with
chemotherapy agents is being evaluated (Reardon et al, 2008).
However, the molecular alterations underlying glioma patients’
response to PDGFRA antagonists are unknown. One study
analysed the prevalence of PDGFRA mutations in patients enrolled
in a phase I/II study of imatinib mesylate in recurrent malignant
gliomas; however, no activating mutations were observed
(Wen et al, 2006). The in vitro studies using PDGFR-targeted
drugs (e.g., imatinib) have provided conflicting information about
the molecular underpinning of sensitivity to those agents.
Although some suggested that sensitivity to targeted agents is
associated with overall PDGFR activation; others point to the
putative role of PDGFRB or failed to show any association between
PDGFR status and response to imatinib (Gross et al, 2006;
Ha¨gerstrand et al, 2006; Servidei et al, 2006).
Here, we observed PDGFA expression in 81.2% of gliomas.
Overall, PDGFA was highly expressed in all histological types of
gliomas. Previous studies on PDGFA mRNA expression reported
Figure 3 CISH analysis of PDGFRA in a glioblastoma (A) with PDGFRA amplification ( 600, no HE counterstaining) and other (B) without PDFRA
amplification ( 600, no HE counterstaining). The colour reproduction of this figure is available on the html full text version of the article.
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Figure 4 Ideogram and microarray CGH chromosome plots of chromosome 4, in which PDGFRA gene is located, for a case without (A) and other with
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high levels of PDGFA in gliomas (Maxwell et al, 1990; Mapstone,
1991; Hermanson et al, 1992; Di Rocco et al, 1998). It should be
noted, however, that there is a paucity of data on prevalence of
PDGFA protein expression in primary glioma specimens. We have
previously shown that 100% of gliosarcomas express PDGFA (Reis
et al, 2005). PDGFRA expression was detected in 29.6% of gliomas,
and more frequently expressed in 45–60% of malignant astrocytic
tumours. These frequencies are in agreement with previous
studies, where approximately 50% for malignant astrocytomas
were reported to express this receptor (Nister et al, 1988, 1991;
Hermanson et al, 1992; Black et al, 1996; Di Rocco et al, 1998;
Ribom et al, 2002; Varela et al, 2004; Liang et al, 2008; Takei et al,
2008; Thorarinsdottir et al, 2008). A previous study showed
PDGFRA expression in approximately 50% of gliomas and a
correlation with poor prognosis in low-grade gliomas (Varela et al,
2004). However, in a report of 40 patients with grade II
astrocytomas and oligoastrocytomas, there was an association
between high PDGFRA expression and a favourable patient
outcome (Ribom et al, 2002). Recently, Liang et al, (2008) in a
paediatric high-grade glioma series failed to find any significant
impact of PDGFRA expression on survival. In our series, PDGFRA
expression was not correlated with patients’ survival. Interestingly,
we found that the absence of PDGFA expression is significantly
associated with age and poor prognosis in patients with glioma.
Given the retrospective nature of our study, further analysis of the
prognostic impact of PDGFA and PDGFRA expression in gliomas
is warranted.
Overexpression of RTKs in cancer has been shown to be driven
by underlying genetic events in a substantial proportion of cases
(Gschwind et al, 2004). For instance, KIT overexpression in GISTs
is driven by activating KIT mutations (Gomes et al, 2008), whereas
HER2 overexpression in breast cancer is driven by HER2 gene
amplification (Arriola et al, 2008). Here, we investigated the
prevalence of PDGFRA-activating mutations and gene amplifica-
tion in gliomas. In agreement with previous studies (Hartmann
et al, 2004; Rand et al, 2005; Reis et al, 2005; Sihto et al, 2005; Wen
et al, 2006; McLendon et al, 2008; Parsons et al, 2008), no
PDGFRA-activating mutations were found. However, four silent
mutations and an intronic insertion were identified. Apart from
two silent mutations in PDGFRA exon 12, the other mutations have
been previously described and considered to be genetic poly-
morphisms (http://www.ncbi.nlm.nih.gov/projects/SNP/; Carvalho
et al, 2005; Reis et al, 2005; Wen et al, 2006). The impact of these
genetic polymorphisms in PDGFRA function remains to be
elucidated.
PDGFRA gene amplification analysis revealed PDGFRA ampli-
fication in 21.1% (12 out of 57) of gliomas, a frequency similar to
that described in previous studies (Fleming et al, 1992; Kumabe
et al, 1992; Smith et al, 2000; Alonso et al, 2005; Arjona et al, 2005;
Puputti et al, 2006; Beroukhim et al, 2007; McLendon et al, 2008).
We have further shown by aCGH that the amplicon encompasses a
region of 3.6Mb, which, in addition to PDGFRA, also includes KIT
and KDR oncogenes. Co-amplification of these three oncogenes
has already been detected with other methodologies in gliomas
(Joensuu et al, 2005; Puputti et al, 2006; Holtkamp et al, 2007). A
statistically significant association between PDGFRA amplification
and overexpression was found only in diffuse astrocytomas (grade
II). Given that PDGFRA overexpression appears to be an early
event in gliomagenesis (Hermanson et al, 1996), our results
provide support to the contention that gene amplification may be
one of the underlying mechanisms at this stage. In a way akin to
other oncogenes, such as EGFR, overexpression of PDGFRA was
more pervasive than gene amplification. It should be noted,
however, that there were B42% of cases with PDGFRA amplifica-
tion that lacked PDGFRA protein expression, suggesting that in
some cases the target of 4q12 amplification may be a gene other
than PDGFRA.
In conclusion, here we show that PDGFA is expressed in
different types of gliomas and its absence is associated with a poor
prognosis. PDGFRA is significantly highly expressed in malignant
astrocytic tumours. Based on the concurrent expression of PDGFA
and PDGFRA in glioblastomas, it could be hypothesised that
autocrine/paracrine loops may be present in these tumours,
corroborating the importance of this signalling pathway in gliomas
(Nister et al, 1991; Guha et al, 1995; Fomchenko and Holland,
2007). PDGFRA gene amplification may be the underlying genetic
mechanism driving PDGFRA overexpression in gliomas. However,
B42% of cases with amplification of PDGFRA did not display
PDGFRA protein expression, suggesting that a gene other than
PDGFRA may be the driver of this amplicon. Further studies are
needed to correlate these molecular alterations and response to
anti-PDGFRA drugs and to investigate the alternative drivers of the
4q12 amplicon. However, our results provide a step forward in the
identification of a molecular basis for tailoring the therapies for
specific subgroups of glioma patients.
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